Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 5/20 | 0.70 |
| ▸ | MAOB | P27338 | 3/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.70 |
| ▸ | SDHA | P31040 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CALML3 | P27482 | 1/20 | 0.70 |
| ▸ | F10 | P00742 | 5/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30114894 | 1.00 | MAOA (0.70) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL4573661 | 1.00 | MAOA (0.70) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6335205 | 0.90 | MAOA (0.57) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL16701349 | 0.90 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL16701350 | 0.90 | MAOA (0.74) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL12964559 | 0.89 | MAOA (0.56) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL13034192 | 0.89 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL6097822 | 0.89 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL3328441 | 0.89 | MAOA (0.76) | MAOAMAOBPTGS1SDHALMNA | |
| SCHEMBL12950996 | 0.89 | MAOA (0.72) | MAOAMAOBPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115677679-A | Oxazolidinone compound containing biaryl hydrazone structure and preparation method and application thereof | 沈阳药科大学 | 2023-02-03 | — | — | CN | disclosed |
| US-9487545-B2 | Fused ring-containing oxazolidinones antibiotics | Xuanzhu Pharma Co., Ltd. (CN) | 2016-11-08 | — | — | US | disclosed |
| US-9359344-B2 | Biaryl heterocycle substituted oxazolidinone antibacterial agents | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-9359344-B2 | Biaryl heterocycle substituted oxazolidinone antibacterial agents | Xuanzhu Pharma Co., Ltd. (CN) | 2016-06-07 | — | — | US | disclosed |
| US-8853258-B2 | C-linked hydroxamic acid derivatives useful as antibacterial agents | PFIZER INC. (US) | 2014-10-07 | — | — | US | disclosed |
| US-8846669-B2 | Oxazolidinone derivative and medical composition containing same | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-09-30 | — | — | US | disclosed |
| US-20140243288-A1 | FUSED RING-CONTAINING OXAZOLIDINONES ANTIBIOTICS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-28 | — | — | US | disclosed |
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-21 | — | — | US | disclosed |
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-21 | — | — | US | disclosed |
| EP-2762480-A1 | OXAZOLIDINONE ANTIBIOTICS CONTAINING FUSED RING | Xuanzhu Pharma Co., Ltd. (CN) | 2014-08-06 | — | — | EP | disclosed |
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | LEGOCHEM BIOSCIENCES, INC. (KR) | 2014-06-26 | — | — | US | disclosed |
| EP-2692727-A2 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | LegoChem Biosciences, Inc. (KR) | 2014-02-05 | — | — | EP | disclosed |
| CN-103030634-A | Bicyclo-containing oxazolidinone antibiotics | KBP BIOSCIENCES CO LTD | 2013-04-10 | — | — | CN | disclosed |
| WO-2013044845-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINON ANTIBACTERIAL DRUG | 山东轩竹医药科技有限公司 (CN) | 2013-04-04 | — | — | WO | disclosed |
| WO-2012134188-A2 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | 주식회사 레고켐 바이오사이언스 (KR) | 2012-10-04 | — | — | WO | disclosed |
| EP-2488489-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | Pfizer Inc. (US) | 2012-08-22 | — | — | EP | disclosed |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | BROWN MATTHEW FRANK (US) | 2012-08-09 | — | — | US | disclosed |
| CN-102153547-A | Oxazolidinone antibiotic containing parallel rings | SHANDONG XUANZHU PHARMACEUTICAL CO LTD OWN | 2011-08-17 | — | — | CN | disclosed |
| WO-2011045703-A2 | C-LINKED HYDROXAMIC ACID DERIVATIVES USEFUL AS ANTIBACTERIAL AGENTS | PFIZER INC. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2008069619-A1 | NOVEL OXAZOLIDINONE DERIVATIVES, PROCESS FOR PREPARING THEREOF AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | LEGOCHEM BIOSCIENCE LTD. (KR) | 2008-06-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140179691-A1 | NOVEL OXAZOLIDINONE DERIVATIVE AND MEDICAL COMPOSITION CONTAINING SAME | OXA1L, PAM, ABCC1 | MAOA 3122/4885MAOB 2328/4885PTGS1 2505/4885 |
| US-20120202777-A1 | C-Linked Hydroxamic Acid Derivatives Useful As Antibacterial Agents | HAX1, LPXN, AGXT | MAOA 841/4885MAOB 880/4885PTGS1 815/4885 |
| US-20140235584-A1 | BIARYL HETEROCYCLE SUBSTITUTED OXAZOLIDINONE ANTIBACTERIAL AGENTS | OXA1L, CYP2C19, CBR3 | MAOA 847/4885MAOB 285/4885PTGS1 3037/4885 |
| US-20140243288-A1 | FUSED RING-CONTAINING OXAZOLIDINONES ANTIBIOTICS | OXA1L, O60361, OXER1 | MAOA 2329/4885MAOB 1150/4885PTGS1 3007/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.